LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2016 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the expansion of its management team with the appointment of Tricia Suvari as chief legal officer.
“Tricia brings a wealth of experience managing the complex legal and business situations that arise in rapidly growing biopharmaceutical companies,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her knowledge and expertise managing business development opportunities, financings, and commercial compliance responsibilities will serve well in this role as we continue to grow as a company.”
Ms. Suvari has approximately 20 years of experience in the life sciences industry. She previously served in several senior roles at CV Therapeutics, ultimately as senior vice president, general counsel and chief compliance officer. At CV Therapeutics, she led the in-house legal team as the company transitioned from an R&D-stage company to a commercial-stage company with marketed products in the US and EU and multiple partnering arrangements. Prior to CV Therapeutics, she served as senior counsel at Genentech, where she completed many complex business development and licensing transactions and advised on legal compliance for several commercial products. She has also served as an independent consultant, supporting biopharmaceutical companies ranging from early-stage private companies to public companies. Most recently before joining GBT, Ms. Suvari served as a vice president and general counsel at the non-profit Peninsula Open Space Trust, where she led the land transactions team responsible for negotiating, structuring and funding complex conservation-oriented real estate transactions. Ms. Suvari earned her Bachelor of Sciences degree in Geology and Geophysics from Yale University and her J.D. degree from Harvard Law School.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in a Phase 1/2 study in both healthy subjects and adults with SCD and a Phase 2a study in adolescents with SCD. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in an ongoing Phase 2a study in patients with idiopathic pulmonary fibrosis. Additionally, GBT is also engaged in research and development activities with an oral kallikrein inhibitor for the prevention of hereditary angioedema attacks. To learn more, please visit: www.globalbloodtx.com.
Contact Information: Myesha Edwards (investors) Global Blood Therapeutics 650-351-4730 [email protected] Julie Normart (media) BrewLife 415-946-1087 [email protected]
